The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global PD-1 and PD-L1 Immunotherapy Market Research Report 2025

Global PD-1 and PD-L1 Immunotherapy Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1896578

No of Pages : 83

Ask Your Query
Synopsis
The global PD-1 and PD-L1 Immunotherapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for PD-1 and PD-L1 Immunotherapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for PD-1 and PD-L1 Immunotherapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for PD-1 and PD-L1 Immunotherapy in Solid Tumors is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of PD-1 and PD-L1 Immunotherapy include AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck, Pfizer, Roche, Novartis, Jiangsu HengRui Medicine and Innovent, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for PD-1 and PD-L1 Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1 and PD-L1 Immunotherapy.
Report Scope
The PD-1 and PD-L1 Immunotherapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global PD-1 and PD-L1 Immunotherapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PD-1 and PD-L1 Immunotherapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Bristol-Myers Squibb
F. Hoffmann-La Roche
Merck
Pfizer
Roche
Novartis
Jiangsu HengRui Medicine
Innovent
Eli Lilly
GlaxoSmithKline
Segment by Type
PD-1 inhibitor
PD-L1 inhibitor
Segment by Application
Solid Tumors
Blood-related Tumors
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PD-1 and PD-L1 Immunotherapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global PD-1 and PD-L1 Immunotherapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 PD-1 inhibitor
1.2.3 PD-L1 inhibitor
1.3 Market by Application
1.3.1 Global PD-1 and PD-L1 Immunotherapy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Solid Tumors
1.3.3 Blood-related Tumors
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global PD-1 and PD-L1 Immunotherapy Market Perspective (2019-2030)
2.2 PD-1 and PD-L1 Immunotherapy Growth Trends by Region
2.2.1 Global PD-1 and PD-L1 Immunotherapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 PD-1 and PD-L1 Immunotherapy Historic Market Size by Region (2019-2024)
2.2.3 PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Region (2025-2030)
2.3 PD-1 and PD-L1 Immunotherapy Market Dynamics
2.3.1 PD-1 and PD-L1 Immunotherapy Industry Trends
2.3.2 PD-1 and PD-L1 Immunotherapy Market Drivers
2.3.3 PD-1 and PD-L1 Immunotherapy Market Challenges
2.3.4 PD-1 and PD-L1 Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top PD-1 and PD-L1 Immunotherapy Players by Revenue
3.1.1 Global Top PD-1 and PD-L1 Immunotherapy Players by Revenue (2019-2024)
3.1.2 Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Players (2019-2024)
3.2 Global PD-1 and PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by PD-1 and PD-L1 Immunotherapy Revenue
3.4 Global PD-1 and PD-L1 Immunotherapy Market Concentration Ratio
3.4.1 Global PD-1 and PD-L1 Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Immunotherapy Revenue in 2023
3.5 PD-1 and PD-L1 Immunotherapy Key Players Head office and Area Served
3.6 Key Players PD-1 and PD-L1 Immunotherapy Product Solution and Service
3.7 Date of Enter into PD-1 and PD-L1 Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 PD-1 and PD-L1 Immunotherapy Breakdown Data by Type
4.1 Global PD-1 and PD-L1 Immunotherapy Historic Market Size by Type (2019-2024)
4.2 Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Type (2025-2030)
5 PD-1 and PD-L1 Immunotherapy Breakdown Data by Application
5.1 Global PD-1 and PD-L1 Immunotherapy Historic Market Size by Application (2019-2024)
5.2 Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America PD-1 and PD-L1 Immunotherapy Market Size (2019-2030)
6.2 North America PD-1 and PD-L1 Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America PD-1 and PD-L1 Immunotherapy Market Size by Country (2019-2024)
6.4 North America PD-1 and PD-L1 Immunotherapy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe PD-1 and PD-L1 Immunotherapy Market Size (2019-2030)
7.2 Europe PD-1 and PD-L1 Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe PD-1 and PD-L1 Immunotherapy Market Size by Country (2019-2024)
7.4 Europe PD-1 and PD-L1 Immunotherapy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size (2019-2030)
8.2 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size by Region (2019-2024)
8.4 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America PD-1 and PD-L1 Immunotherapy Market Size (2019-2030)
9.2 Latin America PD-1 and PD-L1 Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America PD-1 and PD-L1 Immunotherapy Market Size by Country (2019-2024)
9.4 Latin America PD-1 and PD-L1 Immunotherapy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size (2019-2030)
10.2 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size by Country (2019-2024)
10.4 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca PD-1 and PD-L1 Immunotherapy Introduction
11.1.4 AstraZeneca Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Detail
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Introduction
11.2.4 Bristol-Myers Squibb Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 F. Hoffmann-La Roche
11.3.1 F. Hoffmann-La Roche Company Detail
11.3.2 F. Hoffmann-La Roche Business Overview
11.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Introduction
11.3.4 F. Hoffmann-La Roche Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.3.5 F. Hoffmann-La Roche Recent Development
11.4 Merck
11.4.1 Merck Company Detail
11.4.2 Merck Business Overview
11.4.3 Merck PD-1 and PD-L1 Immunotherapy Introduction
11.4.4 Merck Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.4.5 Merck Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer PD-1 and PD-L1 Immunotherapy Introduction
11.5.4 Pfizer Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Roche
11.6.1 Roche Company Detail
11.6.2 Roche Business Overview
11.6.3 Roche PD-1 and PD-L1 Immunotherapy Introduction
11.6.4 Roche Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.6.5 Roche Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis PD-1 and PD-L1 Immunotherapy Introduction
11.7.4 Novartis Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.7.5 Novartis Recent Development
11.8 Jiangsu HengRui Medicine
11.8.1 Jiangsu HengRui Medicine Company Detail
11.8.2 Jiangsu HengRui Medicine Business Overview
11.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Introduction
11.8.4 Jiangsu HengRui Medicine Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.8.5 Jiangsu HengRui Medicine Recent Development
11.9 Innovent
11.9.1 Innovent Company Detail
11.9.2 Innovent Business Overview
11.9.3 Innovent PD-1 and PD-L1 Immunotherapy Introduction
11.9.4 Innovent Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.9.5 Innovent Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Detail
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly PD-1 and PD-L1 Immunotherapy Introduction
11.10.4 Eli Lilly Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.10.5 Eli Lilly Recent Development
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Detail
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Introduction
11.11.4 GlaxoSmithKline Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.11.5 GlaxoSmithKline Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock